top of page
  • Facebook
  • White Twitter Icon
  • Soundcloud
  • White Instagram Icon
  • LinkedIn
  • TikTok

Cannabis for Pain: CBD & Beta-caryophyllene for Chronic Pain

Updated: Apr 24, 2023

Welcome to homework assignment CPS 1.10 in the Cannabis for Pain seminar from Higher Learning LV. This seminar provides a review of recently published peer-reviewed scientific research on the topic of the potential medicinal efficacy of cannabis for pain. This assignment in particular focuses on a study published in 2023 about the potential efficacy of the cannabinoid CBD and the terpene beta-caryophyllene to reduce chronic pain resulting from spinal cord injury.


When you complete this homework assignment, simply click the link at the bottom of the article to return to the master page for this seminar.

A 2023 study entitled "Combined Non-psychoactive Cannabis Components Cannabidiol and β-caryophyllene Reduce Chronic Pain via CB1 Interaction in a Rat Spinal Cord Injury Model" that was published in the journal PLOS ONE had the goal of assessing the potential of cannabis cannabinoids to reduce neuropathic pain resulting from spinal cord injury (SCI).

Want to read more?

Subscribe to curtarobbins.wixsite.com to keep reading this exclusive post.

Higher Learning LV

There are many ways to learn from us, including 👇🏽

Teaching the Commerce + Chemistry of Cannabis™

Did You Know?

The cannabis genome produces 100+ cannabinoids, 150+ terpenes, and 20 flavonoids.

These phytomolecules interact with the human endocannabinoid system (ECS) to produce wellness.

But it gets complex. Biphasic response curves, biosynthetic pathways, and acidic precursors all commingle. Subscribe to learn how. 

Copyright © 2023 Higher Learning LV. All Rights Reserved. Unauthorized reuse strictly prohibited.

bottom of page